
### [NCIT:C4337](http://purl.obolibrary.org/obo/NCIT_C4337)
**Label:** Mantle Cell Lymphoma

**Subclasses:** [NCIT:C27411](http://purl.obolibrary.org/obo/NCIT_C27411) (Colon Mantle Cell Lymphoma), [NCIT:C27441](http://purl.obolibrary.org/obo/NCIT_C27441) (Small Intestinal Mantle Cell Lymphoma), [NCIT:C7229](http://purl.obolibrary.org/obo/NCIT_C7229) (Blastoid Variant Mantle Cell Lymphoma), [NCIT:C7306](http://purl.obolibrary.org/obo/NCIT_C7306) (Splenic Mantle Cell Lymphoma), [NCIT:C27440](http://purl.obolibrary.org/obo/NCIT_C27440) (Gastric Mantle Cell Lymphoma), [NCIT:C8489](http://purl.obolibrary.org/obo/NCIT_C8489) (Recurrent Mantle Cell Lymphoma), [NCIT:C45266](http://purl.obolibrary.org/obo/NCIT_C45266) (Cutaneous Mantle Cell Lymphoma), [NCIT:C9202](http://purl.obolibrary.org/obo/NCIT_C9202) (Stage II Mantle Cell Lymphoma), [NCIT:C8465](http://purl.obolibrary.org/obo/NCIT_C8465) (Stage I Mantle Cell Lymphoma), [NCIT:C8862](http://purl.obolibrary.org/obo/NCIT_C8862) (Refractory Mantle Cell Lymphoma), [NCIT:C8486](http://purl.obolibrary.org/obo/NCIT_C8486) (Stage IV Mantle Cell Lymphoma), [NCIT:C8483](http://purl.obolibrary.org/obo/NCIT_C8483) (Stage III Mantle Cell Lymphoma), [NCIT:C96505](http://purl.obolibrary.org/obo/NCIT_C96505) (Colorectal Mantle Cell Lymphoma), [NCIT:C39747](http://purl.obolibrary.org/obo/NCIT_C39747) (Pleomorphic Variant Mantle Cell Lymphoma), 

**Class expressions from DL-Learner:**

- Thing 54.16%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3880](http://purl.obolibrary.org/obo/NCIT_C3880) (Eyelid Nevus))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38784](http://purl.obolibrary.org/obo/NCIT_C38784) (Apoptosis Pathway))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38770](http://purl.obolibrary.org/obo/NCIT_C38770) (Squamous Differentiation))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38762](http://purl.obolibrary.org/obo/NCIT_C38762) (Thyroid Gland Mucoepidermoid Carcinoma))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3876](http://purl.obolibrary.org/obo/NCIT_C3876) (Gastric Leiomyoma))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38759](http://purl.obolibrary.org/obo/NCIT_C38759) (EBV Infection))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38732](http://purl.obolibrary.org/obo/NCIT_C38732) (Defective Alpha Heavy Chain Present))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38731](http://purl.obolibrary.org/obo/NCIT_C38731) (Villous Atrophy))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38730](http://purl.obolibrary.org/obo/NCIT_C38730) (Lymphoepithelial Lesion))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38727](http://purl.obolibrary.org/obo/NCIT_C38727) (Villous Lymphocyte))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38721](http://purl.obolibrary.org/obo/NCIT_C38721) (Nuclear Pleomorphism))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38710](http://purl.obolibrary.org/obo/NCIT_C38710) (Defective Gamma Heavy Chain Present))) 37.21%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3870](http://purl.obolibrary.org/obo/NCIT_C3870) (Lymphangitic Carcinomatosis))) 37.21%


